GSKGLAXF -0.85%75 Return-on-Tangible-Asset is 18.54% as of Mar. 2026, which is 55% above its 10-year median of 11.93. GuruFocus rates GLAXF with a GF Score™ of 75/100 and a GF Value™ of $21.13 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 1,003 Drug Manufacturers companies, GSK ranks better than 89.53% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. GSK's annualizedNet Income for the quarter that ended in Mar. 2026 was $9,264 Mil. GSK's average total tangible assets for the quarter that ended in Mar. 2026 was $49,964 Mil. Therefore, GSK's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 18.54%.
The historical rank and industry rank for GSK's Return-on-Tangible-Asset or its related term are showing as below:
GLAXF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 2.77 Med: 11.93 Max: 38.72
Current: 15.6
During the past 13 years, GSK's highest Return-on-Tangible-Asset was 38.72%. The lowest was 2.77%. And the median was 11.93%.
GLAXF's Return-on-Tangible-Asset is ranked better than 89.53% of 1003
companies
in the Drug Manufacturers industry
Industry Median: 3.13
vs GLAXF: 15.60
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
GSK Return-on-Tangible-Asset Related Terms
GSK Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for GSK's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GLAXF vs LLY, JNJ, ABBV: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - General subindustry, GSK's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GSK Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GSK's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where GSK's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 18.54% mean?
GSK (GLAXF) has a Return-on-Tangible-Asset of 18.54% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on GSK and its competitors. This is 55% above median its historical median of 11.93. Over the past decade, GSK's Return-on-Tangible-Asset has ranged from 2.77 to 38.72. According to the industry distribution chart, GSK ranks #105 out of 1003 companies in the Drug Manufacturers industry, placing it in the top 10.5%.
Is GSK's Return-on-Tangible-Asset too high?
GSK's current Return-on-Tangible-Asset of 18.54% is 55% above median its 10-year median of 11.93. Over the past 10 years, this metric has ranged from a low of 2.77 to a high of 38.72. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.13. GSK's value of 18.54% is 492.3% above this industry median. Based on the distribution chart, GSK ranks #105 out of 1003 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, GSK has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's Return-on-Tangible-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GSK ranks #105 out of 1003 companies for Return-on-Tangible-Asset. This places GSK in the top 11% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.13. GSK's value of 18.54% is 492.3% above this benchmark. Historically, GSK's own Return-on-Tangible-Asset has ranged from 2.77 to 38.72 over the past decade. While the company's 10-year median is 11.93 vs. the industry median of 3.13, GSK has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.13, based on 1,003 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GSK's current Return-on-Tangible-Asset of 18.54% is 492.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on GSK and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GSK's current Return-on-Tangible-Asset is 18.54%, which is 55% above median its own 10-year median of 11.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (GLAXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.13, compared to a current price of $25.12 — trading 18.9% above its estimated fair value. The current Return-on-Tangible-Asset is 18.54%, which is 55% above median its 10-year median of 11.93 and 492.3% above the Drug Manufacturers industry median of 3.13. GSK's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For GSK (GLAXF), the current Return-on-Tangible-Asset is 18.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GSK (GLAXF) Overvalued in 2026?
Based on GuruFocus' analysis, GSK stock appears to be overvalued.
The current stock price of $25.12 is trading 18.9% above its estimated GF Value™ of $21.13.
GuruFocus considers GSK to be Modestly Overvalued.
Key valuation signals for GLAXF:
Return-on-Tangible-Asset: 18.54% (55% above median its 10-year median of 11.93)
GF Value™: $21.13 vs. price of $25.12 (18.9% above fair value)
Industry Position: 492.3% above the Drug Manufacturers median (#105 of 1003)
No single metric tells the full story. See the GLAXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
75GF Score
Get the complete analysis for GLAXF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLAXF has been successfully added to your 
